Gracell Biotechnologies Inc. (GRCL) Stock
GRCL is no longer traded. Gracell Biotechnologies was delisted from the Nasdaq in February 2024.
Prices on this page are historical; the last trade was February 21, 2024 at $10.25.
Gracell Biotechnologies stock price history
GRCL final trading statistics
- Final close
- $10.25
- Final trading day
- Feb 21, 2024
- Market cap at delisting
- $989.87M
- Shares outstanding
- 96.57M
- Final 52-week range
- $1.40 – $10.44
- Avg. volume (final 3 mo.)
- 1,456,175
- All-time high (split-adj.)
- $30.57 · Feb 2021
- All-time low (split-adj.)
- $1.45 · Apr 2023
- Return since IPO
- -59.1%
- Beta
- -0.34
- Book value / share
- $16.90
- Price / book
- 0.61
Gracell Biotechnologies annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$497.0M | — |
| FY2022 | $0.00 | -$607.5M | -$1.30 |
| FY2021 | $366.0K | -$465.9M | -$1.05 |
| FY2020 | $0.00 | -$197.2M | -$0.24 |
| FY2019 | $0.00 | -$132.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
Gracell Biotechnologies stock FAQ
What happened to Gracell Biotechnologies stock?
Gracell Biotechnologies stock was delisted from the Nasdaq. Its final close was $10.25 on February 21, 2024.
Is GRCL stock still trading?
No. GRCL was delisted from the Nasdaq in February 2024 and no longer trades on a U.S. exchange.
What was the last price of GRCL stock?
GRCL closed at $10.25 on its final trading day, February 21, 2024, for a market value of about $989.87M.
What were Gracell Biotechnologies's revenue and earnings in its last full fiscal year?
Gracell Biotechnologies reported revenue of $0.00 and net income of -$497.0M in fiscal 2023, its last full year as a public company.
When did Gracell Biotechnologies go public?
Gracell Biotechnologies Inc. stock began trading on January 8, 2021.